Literature DB >> 19660791

Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients.

Thomas J Polascik1, Vladimir Mouraviev.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19660791     DOI： 10.1016/j.urology.2009.02.084

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  6 in total

Review 1.  Focal cryotherapy for prostate cancer.

Authors:  Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

2.  Current state of image-guided focal therapy for prostate cancer.

Authors:  Rafael R Tourinho-Barbosa; Bradford J Wood; Andre Luis Abreu; Bruno Nahar; Toshitaka Shin; Selcuk Guven; Thomas J Polascik
Journal:  World J Urol       Date:  2020-05-22       Impact factor: 4.226

3.  Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease.

Authors:  S Punwani; M Emberton; M Walkden; A Sohaib; A Freeman; H Ahmed; C Allen; A Kirkham
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

4.  Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy.

Authors:  Stephanie T Chang; Antonio C Westphalen; Priyanka Jha; Adam J Jung; Peter R Carroll; John Kurhanewicz; Fergus V Coakley
Journal:  J Magn Reson Imaging       Date:  2013-05-16       Impact factor: 4.813

5.  Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings.

Authors:  Philip Quann; David F Jarrard; Wei Huang
Journal:  Int J Clin Exp Pathol       Date:  2010-03-30

6.  Pros and cons of focal therapy for localised prostate cancer.

Authors:  Luigi Mearini; Massimo Porena
Journal:  Prostate Cancer       Date:  2011-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.